Clinical Trials on Pemphigus Vulgaris

Total 918 results

Galderma R&D

Completed

Safety and Efficacy of CD10367 in Psoriasis Vulgaris

Psoriasis Vulgaris

France
Prof. Kristian Reich

Completed

Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP) (METOP)

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Pfizer

Completed

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Psoriasis Vulgaris

Germany
University of Minnesota
Allergan

Completed

Use of Botulinum Toxin to Treat Psoriasis

Psoriasis Vulgaris

United States
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

Ireland, Germany, United Kingdom, Canada, Sweden
Circassia Limited
Bioskin GmbH

Completed

Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Technische Universität Dresden

Completed

Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Psoriasis Vulgaris

Germany
Assiut University

Not yet recruiting

Botox Versus Calcipotriol in Psoriasis Vulgaris

Psoriasis Vulgaris
Badr University

Recruiting

Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris

Psoriasis Vulgaris

Egypt
University of California, San Francisco
Bristol-Myers Squibb

Not yet recruiting

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Psoriasis Vulgaris

United States
University of California, San Francisco
Sun Pharmaceutical Industries Limited

Recruiting

Psoriatic Immune Response to Tildrakizumab

Psoriasis Vulgaris

United States
Ismart

Not yet recruiting

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Psoriasis Vulgaris
Odense University Hospital

Completed

Improvement of Psoriasis Patients' Adherence to Topical Drugs

Psoriasis Vulgaris

Denmark
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. (BIOLOPTIM-SEC)

Psoriasis Vulgaris

Belgium
Dermatology Consulting Services, PLLC

Completed

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Psoriasis Vulgaris

United States
University Hospital, Ghent
University Ghent

Completed

Modified Intermittent Fasting in Psoriasis (MANGO)

Psoriasis | Psoriasis Vulgaris

Belgium
Kadmon Corporation, LLC

Completed

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

Psoriasis Vulgaris

United States
Kadmon Corporation, LLC

Completed

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma
CMIC Co, Ltd. Japan

Completed

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

PSOREAL - Managing PSOriasis in the REAL World (PSOREAL)

Psoriasis Vulgaris

United Kingdom, Canada, Sweden
LEO Pharma

Completed

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
MC2 Therapeutics

Completed

This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

Psoriasis Vulgaris

Germany, Czechia
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

Psoriasis Vulgaris

United States
Assiut University

Unknown

Glucose Trnsporter and PEDF in Psoriasis

Psoriasis Vulgaris
LEO Pharma

Completed

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study (BODYGUARD)

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
Psoriasis Research Institute of Guangzhou

Completed

Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Netherlands, Poland, Romania
LEO Pharma

Completed

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada, France
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

Psoriasis Vulgaris

Denmark
LEO Pharma

Terminated

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Central South University

Unknown

Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate

Psoriasis Vulgaris

China
Philips Electronics Nederland BV

Completed

Blue Light for Treating Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

Psoriasis Vulgaris

United States

3

Subscribe